Table 3 Tumor mutational burden, microsatellite stability status, and multiplex immunohistochemical predictive biomarkers

TMB (mutations/Mb)

6.98

5.98

3.99

4.99

2.99

9.97

–

–

6.98

–

MSI

MSS

MSS

MSS

MSS

MSS

MSS

MSS

–

MSS

–

Tumor PD-L1 (%)

9.27

11.2

0.3

0.33

0.55

2.19

0

0

3.41

0

Stroma PD-L1 (%)

7.07

20.33

3.99

2.73

3.21

2.14

–

–

0.12

–

Tumor PD-1 (%)

8.08

3.06

0.57

3.71

1.57

3.93

–

–

2.67

–

Stroma PD-1 (%)

7.88

14.3

11.82

11.1

5.63

7.04

–

–

3.67

–

Tumor CD8 (%)

2.42

4.64

2.62

3.75

2.48

4.97

–

–

7.65

–

Stroma CD8 (%)

2.84

11

14.8

7.83

13.51

9.59

–

–

6.77

–

Tumor CD3 (%)

8.58

5.77

5.35

6.85

2.86

11.19

–

–

9.91

–

Stroma CD3 (%)

24.1

23.65

43.44

23.92

17.23

24.9

–

–

6.86

–

Tumor CD68 + CD163- (%)

15.13

6.49

4.31

6.74

14.12

12.2

–

–

–

–

Stroma CD68 + CD163- (%)

12.29

22.61

17.6

11.97

7.4

10.3

–

–

–

–

Tumor CD68 + CD163+ (%)

0.53

0.19

0.54

0.18

0.93

0.7

–

–

–

–

Stroma CD68 + CD163+ (%)

0.62

1.82

1.43

2.63

6.99

1.39

–

–

–

–

Tumor CD56 (%)

3.12

0.22

0.18

4.14

1.11

0.36

–

–

–

–

Stroma CD56 (%)

0.81

0.72

0.28

0.93

0.95

0.32

–

–

–

–